Recursion Pharmaceuticals, Inc. (RXRX) stock
Close on Nov 11, 2026Market cap $1.92BP/E –Yield –
Recursion Pharmaceuticals, Inc. grew revenue 56.2% to $68.23M over the twelve months to Sep 30, 2026. Free cash flow was -$312.48M. At the latest close the market valued the company at $1.92B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.92B
- P/E ratio
- –
- Price to sales
- 28.17
- Price to book
- 2.12
- Dividend yield
- –
- Free cash flow yield
- -16.26%
Fundamentals
- Revenue
- $68.23M
- Net income
- -$475.67M
- EPS, diluted
- -$0.90
- Free cash flow
- -$312.48M
- Book value per share
- $1.67
- Diluted shares
- 543M
Trading
- Next earnings
- Feb 24, 2027 (estimated, before the open)
- Previous close
- $3.55
- Open
- $3.69
- Day's range
- $3.53 – $3.72
- Volume
- 16,595,410
- Average volume (20 days)
- 24,192,857
- Index membership
- Russell 2000 (since Jun 2021), Russell 3000 (since Aug 2021)
- Beta (5 years)
- 2.68
- 52-week range
- $2.77 – $5.24
- RSI (14 days)
- 46.1
- Volatility (1 year)
- 74.4%
- Relative volume
- 0.76×
- WACC
- 17.3%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | RXRX | S&P 500 | Difference | RXRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.7% | -2.4% | −15.3 pts | ||
| 3 months | +7.2% | -1.2% | +8.3 pts | ||
| Year to date | -12.2% | +12.3% | −24.5 pts | ||
| 1 year | -23.8% | +12.4% | −36.2 pts | ||
| 3 years | -34.2% | +78.8% | −113.1 pts | -13.0% | +21.4% |
| 5 years | -79.8% | +75.2% | −155.0 pts | -27.4% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Recursion Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Recursion Pharmaceuticals
Biological Products, (No Diagnostic Substances)
Recursion is a clinical-stage biotechnology company that utilizes an artificial intelligence-native platform to discover and develop therapeutic candidates. The company's operating system combines high-throughput biological data generation, computational small molecule design, and clinical development tools to address high unmet medical needs. Recursion advances an internal pipeline focused on rare diseases and oncology, including clinical-stage programs for familial adenomatous polyposis and advanced solid tumors. Additionally, it collaborates with large biopharmaceutical partners to discover novel targets and small molecule programs across neuroscience, oncology, and immunology.
Company profile, executives and historyRecursion Pharmaceuticals stock: common questions
What is Recursion Pharmaceuticals's stock price?
RXRX closed at $3.59 on Nov 11, 2026, up 1.13% on the day. Over the past 52 weeks it traded between $2.77 and $5.24.
What is Recursion Pharmaceuticals's market cap?
Recursion Pharmaceuticals was worth $1.92B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is RXRX's P/E ratio?
Recursion Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.90), so it has no meaningful P/E ratio.
How much revenue does Recursion Pharmaceuticals make?
Recursion Pharmaceuticals reported revenue of $68.23M for the twelve months to Sep 30, 2026, up 56.2% from a year earlier.
Does Recursion Pharmaceuticals pay a dividend?
No. Recursion Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Recursion Pharmaceuticals report earnings next?
Recursion Pharmaceuticals is expected to report Q4 FY2026 results on Feb 24, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has RXRX stock performed over the past year?
Including dividends, RXRX returned -23.8% over the past year, against +12.4% for the S&P 500.
How many RXRX shares are sold short?
142M shares were sold short at the latest FINRA report, 28.15% of the float, or 6.1 days of average trading volume.
Who are Recursion Pharmaceuticals's competitors?
Companies most similar to Recursion Pharmaceuticals by business, industry and size include CGEN, STRO, CSBR, GLUE, KYMR.
See a number that looks wrong?